Art + Cultural and Creative Products Giving New Life to Cultural Relics
17.11.2022 12:56:00 EET | Business Wire | Press release
An international themed achievement exhibition of “THE BIG DRAW ‒ Ar[t]chaeology: Convergence of Art with Sanxingdui” was held at the Sanxingdui Museum on November 16, 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221116006124/en/
(Photo: Business Wire)
“THE BIG DRAW, UK Arts Charity launched ‒ Ar[t]chaeology: Convergence of Art with Sanxingdui” was co-hosted by Sichuan Provincial Department of Culture and Tourism, Deyang Municipal People’s Government, Sichuan Provincial Cultural Heritage Administration, and Hong Kong Trade Development Council; co-organised by Sichuan Publicity Information Center for Culture and Tourism, Sichuan Provincial Academy of Arts, and Management Committee of Sanxingdui Museum; supported by Sichuan Provincial Cultural Relics and Archaeology Research Institute and Deyang Municipal Bureau of Culture, Radio, TV and Tourism. Since the event was launched in June 2022, it has attracted 33 renowned artists from 22 countries and regions and nearly 2,000 participants from over 80 schools and universities.
Yan Sashuang, Vice Director General of Sichuan Provincial Department of Culture and Tourism, presided over the event of the themed achievement exhibition. Dai Yunkang, Vice Director General of the Publicity Department of the CPC Sichuan Provincial Committee, addressed the event. Dai pointed out that Sichuan is a renowned tourist destination in China for its unique Ba-Shu culture and ancient Shu culture. This event attracted artists, art lovers and children worldwide to portray Sanxingdui in their eyes, breathing new life into cultural relics.
He Ping, vice mayor of Deyang Municipal People’s Government, said this event significantly promoted the creative inheritance of Sanxingdui culture and opened a new chapter in the innovative application of cooperation outcomes.
Jacky Chung, Director of the Chinese mainland of Hong Kong Trade Development Council, pointed out that the event is another proof of the in-depth cooperation between Sichuan’s museums and cultural institutions and Hong Kong-funded enterprises.
Kam Panesar, The Big Draw Brand Ambassador in China said, “The UK's expertise in museum and galleries culture and creative tourism is world class. Together with Sichuan Provisional Bureau for Culture and Tourism is an ingrained part of the UK's Arts & Cultural knowledge to implement people centred cultural and artistic festivals in both the UK and China.”
Sanxingdui Culture and Tourism Development Co., Ltd. and BRDGS Partners Group signed an agreement on cultural and creative products cooperation at the site.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221116006124/en/
Contact information
Sichuan Provincial Department Of Culture and Tourism
Lai Cheuk Fay
ylai18200130301@163.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FlexTrade Expands Portfolio Risk and Analytics Capabilities Through Strategic Partnership with Portx13.7.2026 16:30:00 EEST | Press release
FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, and Portx, an advanced portfolio construction and analytics provider, today announced the integration of Portx’sreal-time portfolio construction, optimization, and risk analytics capabilities into FlexTrade’s integrated buy-side order and execution management system (OEMS), FlexONE. The partnership comes as buy-side firms place greater emphasis on real-time risk management across increasingly complex portfolios, advanced hedging strategies, and supporting operating models. For hedge funds and institutional asset managers, particularly those running multi-strategy or multi-asset approaches, the ability to assess portfolio risk, review pro forma exposures, and act on those insights within the order and execution management workflow is becoming increasingly important. FlexTrade's integration with Portx builds on FlexONE's existing real-time front-office risk analytics capabilities, inclu
Xsolla Connect Returns to Brighton13.7.2026 16:22:00 EEST | Press release
Xsolla, a global video game commerce company, today announced the launch of an exclusive networking event for the UK game development community, Xsolla Connect, taking place with Develop:Brighton 2026 on July 15, 2026. Designed to bring together independent and mid-tier developers, publishers, investors, and industry professionals, the event will offer a focused evening of meaningful connections and actionable insights at one of the UK’s most important annual games gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713748542/en/ Graphic: Xsolla Develop:Brighton has long served as a cornerstone of the European video games industry, drawing developers, publishers, investors, and studio leaders from across the UK and beyond to share knowledge, explore opportunities, and forge lasting business relationships. Xsolla’s event will build on that momentum by providing attendees with a dedicated space to connect with peers
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 15:32:00 EEST | Press release
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company's plans to advance the program globally. The FDA granted RPD Designation based on its determination that A-T is a serious and life-threatening disease that primarily affects individ
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 15:00:00 EEST | Press release
Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT), sensor, and asset data. It helps organizations track and visualize public events, supply chains, and infrastructure to identify and respond to potential threats. ArcGIS Velocity for ArcGIS Enterprise expands cloud-native support to enterprise customers across industries in government and business that rely on firewall protection and internal security compliance. ArcGIS Velocity connects to more than 20 ready-to-use feeds for real-time data providers, including Dataminr, Samsara, Fli
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 15:00:00 EEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
